A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, researchers found in a clinical trial.

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide and leuprolide,

A Gleason score of 9.” Veterans of prostate cancer will know those five words pack a punch. It is a grade-high diagnosis, meaning not only that cancer cells are aggressive but that they can spread quickly and have,

An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid hormone plays a key role in the development and progression of prostate cancer.

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, though overall survival data is still awaited.